Last reviewed · How we verify
CBD, synthetic form — Competitive Intelligence Brief
phase 2
CB1 and CB2 receptors
Pain management, Anxiety disorders
Small molecule
Live · refreshed every 30 min
Target snapshot
CBD, synthetic form (CBD, synthetic form) — CannaMore Biotechs. CBD, a synthetic form, interacts with the body's endocannabinoid system to produce therapeutic effects.
Comparator set (3 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CBD, synthetic form TARGET | CBD, synthetic form | CannaMore Biotechs | phase 2 | CB1 and CB2 receptors | ||
| medical cannabis | medical cannabis | HaEmek Medical Center, Israel | phase 3 | CB1 and CB2 receptors | ||
| THC/CBD | THC/CBD | Azienda Ospedaliera Universitaria Policlinico "G. Martino" | phase 3 | cannabinoid | CB1 and CB2 receptors | |
| Single-dose of cannabis oil | Single-dose of cannabis oil | Hadassah Medical Organization | phase 3 | CB1 and CB2 receptors |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CBD, synthetic form CI watch — RSS
- CBD, synthetic form CI watch — Atom
- CBD, synthetic form CI watch — JSON
- CBD, synthetic form alone — RSS
Cite this brief
Drug Landscape (2026). CBD, synthetic form — Competitive Intelligence Brief. https://druglandscape.com/ci/cbd-synthetic-form. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing